KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: May 14, 2025
-- Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data anticipated in 3Q 2025 --
-- Cash resources of $42.2 million as of March 31, 2025, expected to fund operations into 1Q 2026 --
Read more at globenewswire.comNASDAQ:KALA (8/22/2025, 3:22:00 PM)
9.02
+0.52 (+6.12%)
Find more stocks in the Stock Screener
